These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 24796231)

  • 1. Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J).
    Eguchi Y; Kitajima Y; Hyogo H; Takahashi H; Kojima M; Ono M; Araki N; Tanaka K; Yamaguchi M; Matsuda Y; Ide Y; Otsuka T; Ozaki I; Ono N; Eguchi T; Anzai K;
    Hepatol Res; 2015 Mar; 45(3):269-78. PubMed ID: 24796231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
    Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
    Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liraglutide Decreases Hepatic Inflammation and Injury in Advanced Lean Non-Alcoholic Steatohepatitis.
    Ipsen DH; Rolin B; Rakipovski G; Skovsted GF; Madsen A; Kolstrup S; Schou-Pedersen AM; Skat-Rørdam J; Lykkesfeldt J; Tveden-Nyborg P
    Basic Clin Pharmacol Toxicol; 2018 Dec; 123(6):704-713. PubMed ID: 29953740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
    World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determining whether the effect of liraglutide on non-alcoholic fatty liver disease depends on reductions in the body mass index.
    Shiomi M; Tanaka Y; Takada T; Otori K
    JGH Open; 2020 Oct; 4(5):995-1001. PubMed ID: 33102775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Eslami L; Merat S; Malekzadeh R; Nasseri-Moghaddam S; Aramin H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008623. PubMed ID: 24374462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: A pilot randomized trial.
    Khoo J; Hsiang J; Taneja R; Law NM; Ang TL
    Diabetes Obes Metab; 2017 Dec; 19(12):1814-1817. PubMed ID: 28503750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis.
    Duparc T; Briand F; Trenteseaux C; Merian J; Combes G; Najib S; Sulpice T; Martinez LO
    Am J Physiol Gastrointest Liver Physiol; 2019 Oct; 317(4):G508-G517. PubMed ID: 31460789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study.
    Huang MA; Greenson JK; Chao C; Anderson L; Peterman D; Jacobson J; Emick D; Lok AS; Conjeevaram HS
    Am J Gastroenterol; 2005 May; 100(5):1072-81. PubMed ID: 15842581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Non-Alcoholic Steatohepatitis: A Clinical Review Article.
    Ghazanfar H; Kandhi SD; Nawaz I; Javed N; Abraham MC; Farag M; Mahasamudram J; Patel VB; Altaf F; Patel H
    Cureus; 2021 May; 13(5):e15141. PubMed ID: 34164242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitis.
    Perakakis N; Stefanakis K; Feigh M; Veidal SS; Mantzoros CS
    Liver Int; 2021 Aug; 41(8):1853-1866. PubMed ID: 33788377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD).
    Iogna Prat L; Tsochatzis EA
    Hormones (Athens); 2018 Jun; 17(2):219-229. PubMed ID: 29858843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease.
    Gao H; Zeng Z; Zhang H; Zhou X; Guan L; Deng W; Xu L
    Biol Pharm Bull; 2015; 38(5):694-702. PubMed ID: 25947915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease.
    Khoo J; Hsiang JC; Taneja R; Koo SH; Soon GH; Kam CJ; Law NM; Ang TL
    Liver Int; 2019 May; 39(5):941-949. PubMed ID: 30721572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy.
    Yu X; Hao M; Liu Y; Ma X; Lin W; Xu Q; Zhou H; Shao N; Kuang H
    Eur J Pharmacol; 2019 Dec; 864():172715. PubMed ID: 31593687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial.
    Armstrong MJ; Barton D; Gaunt P; Hull D; Guo K; Stocken D; Gough SC; Tomlinson JW; Brown RM; Hübscher SG; Newsome PN;
    BMJ Open; 2013 Nov; 3(11):e003995. PubMed ID: 24189085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human placental extract treatment for non-alcoholic steatohepatitis non-responsive to lifestyle intervention: A pilot study.
    Shimokobe H; Sumida Y; Tanaka S; Mori K; Kitamura Y; Fukumoto K; Kakutani A; Ohno T; Kanemasa K; Imai S; Hibino S; Yoshikawa T
    Hepatol Res; 2015 Sep; 45(9):1034-1040. PubMed ID: 25297827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials.
    Kalogirou MS; Patoulias D; Haidich AB; Akriviadis E; Sinakos E
    Clin Res Hepatol Gastroenterol; 2021 May; 45(3):101568. PubMed ID: 33309563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease.
    Tian F; Zheng Z; Zhang D; He S; Shen J
    Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30473540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.